[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601497":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":52,"collaborators":25,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":25,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":25,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":39,"whyStopped":25,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"4-Hour HA Group","EXPERIMENTAL","Subjects receive high-flux hemodialysis (HFHD) twice a week and hemoadsorption combined with HFHD (HAHD) once a week. The HAHD session, using a pHA130 cartridge, lasts for the entire 4-hour duration of the dialysis session. Blood flow rate is maintained at 250-350 mL\u002Fmin, consistent with the patient's original HD prescription.",[13],"Device: pHA130 Hemoadsorption + High-Flux Hemodialysis",{"label":15,"type":16,"description":17,"interventionNames":18},"2-Hour HA Group","ACTIVE_COMPARATOR","Subjects receive high-flux hemodialysis (HFHD) twice a week and HAHD once a week. The hemoadsorption component, using a pHA130 cartridge, is performed for the first 2 hours of the session, after which the pHA130 cartridge is removed and the patient continues with standard HFHD for the remaining 2 hours. Blood flow rate during HA is 200-250 mL\u002Fmin.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","pHA130 Hemoadsorption + High-Flux Hemodialysis","A combination blood-purification procedure in which a pHA130 hemoperfusion cartridge is connected in series with a high-flux hemodialyzer. Blood first passes through the HP cartridge to adsorb protein-bound uremic toxins and is then dialyzed. In the 4-hour arm the HP cartridge remains online for the entire 4-hour session; in the 2-hour arm the cartridge is removed after 2 hours and dialysis continues alone for the remaining 2 hours. Blood-flow rates are 250-350 mL\u002Fmin (4-hour arm) or 200-250 mL\u002Fmin (2-hour arm).",[15,9],null,[27],{"name":28,"affiliation":29,"role":30},"Li Zuo","Renal Division, Department of Medicine, Peking University People's Hospital","PRINCIPAL_INVESTIGATOR",[32],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"Liangying Gan","CONTACT","010-88324516","ganl@bjmu.edu.cn",[38],{"facility":5,"status":39,"city":40,"state":41,"zip":25,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":45,"coordinates":46},"Point",[47,48],116.39723,39.9075,{"lat":48,"lon":47},[51],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},{"type":30,"investigatorFullName":28,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Director","100601497","efficacy-of-pha130-hemoadsorption-for-4-hours-p4h-study-100601497",false,"NCT07111260","Efficacy of pHA130 Hemoadsorption for 4 Hours (p4H Study)","Comparison of the Efficacy of Hemoadsorption Combined With Hemodialysis of Different Treatment Durations in Clearing Protein-Bound Uremic Toxins: A Randomized Crossover Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 75 years, regardless of gender\n* Stable maintenance hemodialysis for ≥3 months, with a relatively fixed dialysis regimen\n* Receiving hemodialysis 3 times per week, each session lasting ≥4 hours\n* Single-pool Kt\u002FV (spKt\u002FV) ≥1.2 within 8 weeks prior to enrollment\n* Willing and able to sign the informed consent form\n\nExclusion Criteria:\n\n* Life expectancy less than 1 year\n* White blood cell count \\\u003C 4 × 10⁹\u002FL and\u002For platelet count \\\u003C 60 × 10⁹\u002FL\n* Active or chronic gastrointestinal bleeding, or diagnosed coagulation disorders\n* Active malignant tumor\n* Active infection\n* Pregnant or breastfeeding\n* Participation in another clinical trial within the past month or currently enrolled in one\n* Deemed unsuitable for the study by the investigator","ALL","18 Years","75 Years",{"count":65,"type":66},34,"ESTIMATED","INTERVENTIONAL",[69],"NA","This is an open-label, randomized, crossover study to evaluate the efficacy of extending the duration of hemoadsorption (HA) combined with hemodialysis (HD) from 2 hours to 4 hours for clearing protein-bound uremic toxins, such as Indoxyl Sulfate (IS), in stable maintenance hemodialysis patients. Patients will be randomized to receive either 2-hour HA or 4-hour HA once a week for 8 weeks, then cross over to the other treatment for another 8 weeks after a 2-week washout period. The primary endpoint is the reduction rate of IS.",[72],"End Stage Renal Disease on Dialysis",[74,75],"Hemoadsorption","Duration","2025-08-06",{"date":78,"type":79},"2025-08-08","ACTUAL",{"date":81,"type":79},"2025-07-01",{"date":83,"type":66},"2026-05",{"name":5,"class":6},1]